A Multi-Center, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease

Trial Profile

A Multi-Center, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2013

At a glance

  • Drugs Denufosol (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms TIGER-1
  • Most Recent Events

    • 10 Apr 2012 New trial record
    • 01 Mar 2012 Primary endpoint 'Forced expiratory volume in 1 second at 24 weeks' has been met, according to results of the economic analysis published in Value in Health.
    • 01 Mar 2012 Results of the economic analysis published in Value in Health.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top